Accuray Inc (ARAY)

4.58
0.07 1.70
NASDAQ : Health Care
Prev Close 4.50
Open 4.55
Day Low/High 4.50 / 4.60
52 Wk Low/High 4.75 / 7.54
Volume 72.97K
Avg Volume 798.00K
Exchange NASDAQ
Shares Outstanding 83.00M
Market Cap 369.35M
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Accuray Enters Into New Revolving Loan Agreement

New Loan Expected to Reduce Interest Costs by Approximately $2.0 Million Annually

New Data Reinforce Benefits Of TomoTherapy® Platform For Mainstream Radiation Therapy Treatment Indications

Multiple Studies Presented at ESTRO 36 Demonstrate System Improves Tumor Control withReduced Toxicities

New Data Presented At ESTRO 36 Reinforce Unmatched Versatility And Precision Of The CyberKnife® System

Studies Show the System Provides Excellent Outcomes Throughout the Cancer Treatment Journey, from Primary Cases to Recurrence and Metastatic Disease

Accuray To Showcase CyberKnife® And Radixact™ Systems At ESTRO 2017

Innovations in Hardware and Software Solutions Reinforce the Benefits of Accuray Systems in Treating a Wide Range of Cancer Cases

Accuray Enters Oversold Territory (ARAY)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

CyberKnife® System Provides Effective Treatment Option With Minimal Side Effects And Excellent Cosmesis For Early Stage Breast Cancer Patients

Robotic Radiosurgery System's Unique Motion Management Technique Limits Toxicity and Preserves Cosmesis in Convenient, 5-Fraction Treatment Regimen

First Cancer Patients In Africa Treated With The TomoTherapy® System

Premier Algerian Cancer Center Now Provides Cancer Patients with Leading-Edge Radiation Treatments

CyberKnife® System Provides Long-term Disease Control For Prostate Cancer Patients

Prospective, Multi-institutional Study Shows CyberKnife SBRT Treatment Results in Low PSA Nadir for Low- and Intermediate-risk Prostate Cancer Patients

The Accuray Radixact™ System Receives Shonin Approval

Next-Generation "Smart" TomoTherapy® System Represents Major Step Forward in Treatment Speed, Ease of Use and Adaptive Therapy Capabilities

Miami Cancer Institute Treats First Cancer Patients With The Accuray Radixact™ System

Miami Cancer Institute Treats First Cancer Patients With The Accuray Radixact™ System

Day 1 Experience Demonstrates the Speed and Efficiency of the New System

First Week of ARAY September 15th Options Trading

First Week of ARAY September 15th Options Trading

Investors in Accuray Inc saw new options begin trading this week, for the September 15th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Accuray Continues To Set The Industry Standard For Customer Satisfaction

Accuray Continues To Set The Industry Standard For Customer Satisfaction

MD Buyline Report Shows Composite Overall User Satisfaction Ratings Exceed Industry Average for 14 Consecutive Quarters

Short Interest Moves 12.7% Lower For ARAY

Short Interest Moves 12.7% Lower For ARAY

The most recent short interest data has been released for the 12/30/2016 settlement date, which shows a 963,627 share decrease in total short interest for Accuray Inc , to 6,615,663, a decrease of 12.71% since 12/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Hong Kong Sanatorium & Hospital To Acquire Three RadixactTM Systems

Hong Kong Sanatorium & Hospital To Acquire Three RadixactTM Systems

Hospital will be the First in Asia to Offer Radixact™ System and CyberKnife® M6™ System Patient Treatments

First Cancer Patients In The World Treated With The Smart, New Accuray Radixact™ System

First Cancer Patients In The World Treated With The Smart, New Accuray Radixact™ System

European and U.S. Hospitals Advance Adaptive Cancer Care with Image-Guided Radiation Therapy System

Commit To Buy Accuray At $4, Earn 11.6% Annualized Using Options

Commit To Buy Accuray At $4, Earn 11.6% Annualized Using Options

Investors eyeing a purchase of Accuray Inc shares, but cautious about paying the going market price of $5.08/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the June 2017 put at the $4 strike, which has a bid at the time of this writing of 25 cents.

Commit To Buy Accuray At $4, Earn 11.6% Annualized Using Options

Commit To Buy Accuray At $4, Earn 11.6% Annualized Using Options

Investors eyeing a purchase of Accuray Inc shares, but cautious about paying the going market price of $5.08/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the June 2017 put at the $4 strike, which has a bid at the time of this writing of 25 cents.

Commit To Buy Accuray At $4, Earn 11.6% Annualized Using Options

Commit To Buy Accuray At $4, Earn 11.6% Annualized Using Options

Investors eyeing a purchase of Accuray Inc shares, but cautious about paying the going market price of $5.08/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the June 2017 put at the $4 strike, which has a bid at the time of this writing of 25 cents.

Prospective, Multi-Institutional Study Shows Five Treatments With The CyberKnife® System Provide Excellent Disease Control For Prostate Cancer Patients

Prospective, Multi-Institutional Study Shows Five Treatments With The CyberKnife® System Provide Excellent Disease Control For Prostate Cancer Patients

ASTRO Selects the Data for Center Stage at Largest Annual Meeting of Radiation Oncologists

Accuray To Unveil New Technology At The ASTRO 2016 Annual Meeting

Accuray To Unveil New Technology At The ASTRO 2016 Annual Meeting

Innovations in Hardware and Software Solutions and New Clinical Data Reinforce the Benefits of Accuray Systems in Treating a Wide Range of Cancer Cases

Accuray (ARAY) Stock Sharply Lower After Q4 Results, Guidance

Accuray (ARAY) Stock Sharply Lower After Q4 Results, Guidance

Accuray (ARAY) reported a larger-than-anticipated loss for the 2016 fiscal fourth quarter and a downbeat forecast following Wednesday's closing bell.

Will Accuray (ARAY) Stock Fall on Q4 Miss, Downbeat Outlook?

Will Accuray (ARAY) Stock Fall on Q4 Miss, Downbeat Outlook?

Accuray (ARAY) posted a wider-than-expected loss for the 2016 fiscal fourth quarter after Wednesday's market close.

Accuray CE Marks Its New Radixact™ System

Accuray CE Marks Its New Radixact™ System

Next Generation Image-Guided Radiation Therapy Platform and Integrated Software Solutions are Now Available for Use by Clinicians in the European Union

New Data Show InCise™ Multileaf Collimator For The CyberKnife® M6™ System May Expand Patient Population Eligible For Precise Radiation Treatments

New Data Show InCise™ Multileaf Collimator For The CyberKnife® M6™ System May Expand Patient Population Eligible For Precise Radiation Treatments

Clinical Research on the CyberKnife® System, Including the Multileaf Collimator, Presented at Leading Scientific Meeting for Medical Physicists